research Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.
Search
for
Sort by
Research
240-270 / 1000+ resultsresearch Consensus on the treatment of alopecia areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Safety concerns when using novel medications to treat alopecia
Consider benefits and risks of new alopecia treatments for safety.
research Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Apremilast did not work for treating severe alopecia areata.
research Parsing patterns: Emerging roles of tissue self-organization in health and disease
Understanding tissue self-organization can improve treatments for diseases and advance regenerative medicine.
research Alopecia Areata: An Update on Treatment Options for Children
Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
research Current Treatments for Alopecia Areata
There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
research Novedades terapéuticas en tricología
Recent advances in hair loss treatments show significant progress.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
research The Changing Landscape of Alopecia Areata: The Translational Landscape
New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research A “hair‐raising” history of alopecia areata
The document concludes that understanding and treatments for alopecia areata have significantly advanced, now recognizing it as an autoimmune disorder.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Identification of differentially expressed miRNAs in alopecia areata that target immune-regulatory pathways
Certain microRNAs may help treat alopecia areata by targeting immune pathways.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
research Rethinking the classification of alopecia areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Alopecia in general medicine
The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.
research Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system
New, effective treatments for alopecia areata require innovative approaches targeting the immune system.
research Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.